$NVAX

NOVAVAX INC

Novavax develops vaccines and vaccine technologies for health challenges, serving patients through its own products and partnerships with pharmaceutical companies, research institutions and governments. Its platform combines recombinant protein-based nanoparticles with its proprietary Matrix-M adjuvant. Its commercial product is Nuvaxovid, a COVID-19 vaccine, whose commercialization is led by Sanofi. Novavax also supplies Matrix-M for partner programs, including the R21 malaria vaccine, and advances vaccine candidates and research programs in infectious diseases and other areas. Novavax makes money through vaccine sales and supply agreements, licensing its technologies, and receiving royalties and milestone payments from partners. It also provides research, development and technology-transfer services. Matrix-M is manufactured at its facility in Uppsala, Sweden, as well as through contract manufacturers. Novavax is headquartered in Gaithersburg, Maryland.

AlphAI earnings readThird Quarter 2026 · NOV 5Novavax Reports Third Quarter 2026 Financial Results and Operational HighlightsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
0

No SEC Form 4 filings for $NVAX in the last 30 days.

See all $NVAX insider activity →
Med

Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial

Novavax (NVAX) is exploring new partnerships and advancing its vaccine pipeline. Sanofi is testing a COVID-flu combo vaccine, and Novavax's Nuvaxovid is in U.S. retailers. The company aims for profitability by 2029 and has $6.8B in global COVID-19 vaccine sales last year, with U.S. demand down slightly. Novavax is also developing an oncology vaccine and a C. difficile vaccine, with trials potentially starting in 2027.

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

NVAX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning NVAX (NOVAVAX INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent NVAX coverage spans earnings, financial news and corporate actions.

What's driving NVAX

AlphAI scores every news story that mentions NVAX with an AI model for sentiment and relevance, and aggregates insider trades from NOVAVAX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NVAX

Score

Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial

Novavax (NVAX) is exploring new partnerships and advancing its vaccine pipeline. Sanofi is testing a COVID-flu combo vaccine, and Novavax's Nuvaxovid is in U.S. retailers. The company aims for profitability by 2029 and has $6.8B in global COVID-19 vaccine sales last year, with U.S. demand down slightly. Novavax is also developing an oncology vaccine and a C. difficile vaccine, with trials potentially starting in 2027.

$NVAXHighAI 8/10

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

Novavax gains after Q3 beat, guidance hike

Novavax NVAX reported Q3 2026 revenue of $68.3M, beating estimates by $17.9M due to higher product sales. The company raised its full-year revenue outlook, but total revenue fell 3% YoY. Net loss narrowed 85% YoY to $31.4M as expenses declined. Sanofi SNY is a key partner for Nuvaxovid marketing.

NOVAVAX ($NVAX) Releases Q3 2026 Earnings

NOVAVAX ($NVAX) reported Q3 2026 earnings of -$0.19 per share, beating estimates by $0.15. Revenue was $68.3M, exceeding expectations by $16.9M. Institutional investors showed mixed activity, with some increasing and others decreasing their positions.

$NVAXHighAI 8/10Contract· customer · $125M

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

NOVAVAX INC (NVAX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News & Media Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe October 29, 2026 · The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden

$NVAXMedAI 8/10

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Novavax (NVAX) received a $125 million milestone payment from Sanofi as the latter initiated a Phase 3 trial for a combination influenza-COVID-19 vaccine in Europe. The trial combines Sanofi's high-dose flu vaccine with Novavax's Nuvaxovid COVID-19 vaccine. Novavax may earn additional milestones and royalties, including a $225 million payment upon a U.S. launch. The partnership has generated over $1 billion in revenue for Novavax to date, according to the company.

Related tickers